Identification | Back Directory | [Name]
BenzeneMethanol, a-[[[2-(4-aMinophenyl)ethyl]aMino]Methyl]-, (aR)- | [CAS]
391901-45-4 | [Synonyms]
YM-208876 Mirabegron M16 MiraBegron impurity H Mirabegron metabolite M16 Mirabegron Des-ATAA Impurity (R)-2-((4-AMinophenethyl)aMino)-1-phenylethanol (R)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol (1 R)-2-[(4-aminophenethyl)amino]-1-phenyl-1-ethanol (1R)-2-[2-(4-aminophenyl)ethylamino]-1-phenylethanol (aR)-a-[[[2-(4-Aminophenyl)ethyl]amino]methyl]-benzenemethanol BenzeneMethanol,a-l[2-(4-aMinophenyl)ethyl]aMino]Methyl]-,(aR)- BenzeneMethanol, -[[[2-(4-aMinophenyl)ethyl]aMino]Methyl]-, (R)- BenzeneMethanol, a-[[[2-(4-aMinophenyl)ethyl]aMino]Methyl]-, (aR)- (alphaR)-alpha-[[[2-(4-Aminophenyl)ethyl]amino]methyl]-benzenemethanol Mirabegron Impurity 6/ Mirabegron Intermediate?Impurity ((R)-2-((4-Aminophenethyl)amino)-1-phenylethanol) Mirabegron Impurity 6Q: What is
Mirabegron Impurity 6 Q: What is the CAS Number of
Mirabegron Impurity 6 Q: What is the storage condition of
Mirabegron Impurity 6 Q: What are the applications of
Mirabegron Impurity 6 | [Molecular Formula]
C16H20N2O | [MDL Number]
MFCD28125625 | [MOL File]
391901-45-4.mol | [Molecular Weight]
256.34 |
Chemical Properties | Back Directory | [Melting point ]
97-100°C | [Boiling point ]
447.9±24.0 °C(Predicted) | [density ]
1.137±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
Chloroform (Slightly), DMSO (Sparingly), Methanol (Slightly) | [form ]
Solid | [pka]
13.98±0.20(Predicted) | [color ]
Off-White to Light Beige | [InChI]
InChI=1/C16H20N2O/c17-15-8-6-13(7-9-15)10-11-18-12-16(19)14-4-2-1-3-5-14/h1-9,16,18-19H,10-12,17H2/t16-/s3 | [InChIKey]
TUAHDMSPHZSMQN-QEIABERDNA-N | [SMILES]
[C@@H](O)(C1=CC=CC=C1)CNCCC1=CC=C(N)C=C1 |&1:0,r| |
Hazard Information | Back Directory | [Uses]
(R)-2-((4-Aminophenethyl)amino)-1-phenylethanol is an intermediate in the synthesis of Mirabegron related compounds. irabegron is a potent bladder relaxant and reagent for diabetes remedy. | [Synthesis]
(R)-2-((4-nitrophenylethyl)amino)-1-phenylethanol hydrochloride (Compound I, 15 g, 0.0465 mol) was dissolved in 150 mL of methanol with stirring. Ammonium formate (14.6 g, 0.2325 mol) and 1.5 g of 10% palladium carbon catalyst were subsequently added. The reaction mixture was heated to 65 °C and kept at reflux for 5 hours. The reaction was monitored by thin layer chromatography (TLC, GF254 plate, unfolding agent ratio ethyl acetate:methanol = 5:1) until the fluorescent spots of compound I disappeared. Upon completion of the reaction, methanol was removed by concentration under reduced pressure, followed by the addition of water and ethyl acetate for extraction. The organic phase was evaporated under reduced pressure to remove ethyl acetate to give an off-white solid product (Compound II, 10.91 g) in 91.71% yield. | [References]
[1] Patent: CN105481705, 2016, A. Location in patent: Paragraph 0021; 0022; 0023 [2] Patent: WO2014/132270, 2014, A2. Location in patent: Page/Page column 19 |
|
Company Name: |
LOBERAN PHARMA
|
Tel: |
+91-8368351617 +91-8006595568 |
Website: |
www.loberanpharma.com |
Company Name: |
Lavybens Pharma
|
Tel: |
+91-8790466757 +91-8790466756 |
Website: |
www.lavybenspharma.com |
Company Name: |
Deepa Pharma
|
Tel: |
+91-9029797870 +91-9821962248 |
Website: |
www.deepapharma.com |
|